GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Net Income From Continuing Operations

Neuren Pharmaceuticals (ASX:NEU) Net Income From Continuing Operations : A$124.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Neuren Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2024 was A$12.1 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was A$124.7 Mil.


Neuren Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Neuren Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals Net Income From Continuing Operations Chart

Neuren Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.00 -9.39 -7.90 0.19 159.89

Neuren Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.91 7.38 47.15 112.61 12.07

Neuren Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$124.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuren Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

Neuren Pharmaceuticals Headlines

From GuruFocus

Q1 2020 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 02-10-2024

Q2 2020 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 02-10-2024

Q4 2022 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 02-10-2024

NewMarket Corporation Declares Quarterly Dividend

By Business Wire 08-08-2024

Q3 2020 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 02-10-2024

Q1 2021 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 02-10-2024

NewMarket Corporation Increases Quarterly Dividend

By Business Wire 02-22-2024

Q2 2024 NewMarket Corp Earnings Call Transcript

By GuruFocus Research 07-31-2024